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Abstract
Early graft failure (EGF) is a major risk factor for death after heart transplantation (Htx)
accounting for >40% of deaths within 30 days postoperatively. According to the last
International Society for Heart and Lung Transplantation (ISHLT) consensus state‐
ment, the graft dysfunction (GD) is to be classified into primary (PGD), in case of an
unknown triggering factor or secondary (SGD) where there is a discernible cause such
as acute  rejection,  pulmonary hypertension,  or  known surgical  complications.  The
diagnosis of GD is to be made within 24 h after completion of Htx surgery and a severity
scale for GD should include mild, moderate, or severe grades based on specified criteria.
Mechanical circulatory support (MCS) for GD should be considered when medical
management is not sufficient to support the newly transplanted graft. Currently, extra‐
corporeal membrane oxygenation (ECMO) is widely accepted as treatment of severe
EGF, given its easy and quick setup, the system versatility, the optimal end‐organ
perfusion provided, and the possibility of both biventricular and lung assistance by
usage of a low‐cost single pump.
Keywords: heart transplantation, early graft failure, cardiogenic shock, mechanical
circulatory support, extracorporeal membrane oxygenation
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1. Introduction
A recent examination of early mortality after heart transplantation (Htx), documented in the
International Society for Heart and Lung Transplantation (ISHLT) Registry, reveals that >40%
of deaths within 30 days post‐operatively are due to early graft failure (EGF) [1, 2]. Results get
even worst in the pediatric transplant population where an early mortality of 88% after
diagnosis has been reported [3]. To better define the classification, diagnosis and management
of this condition, a Consensus Conference was organized on April 23, 2013 during the 33rd
Annual ISHLT meeting. There were 71 specialists on this field including cardiologists,
immunologists, pathologists, and surgeons, representing 42 heart centers worldwide. Accord‐
ing to the consensus statement [1], graft dysfunction (GD) has been classified into primary
(PGD), in case of an unknown triggering factor or secondary (SGD) when a discernible cause
such as hyper‐acute rejection, pulmonary hypertension, or known surgical complications [1]
can be identified. The diagnosis of GD is to be made within 24 h after completion of heart
transplantation (Htx) surgery and a severity scale for GD should include mild, moderate, or
severe grades based on specified criteria. Risks are often multifactorial and usually include
donor, recipient, and surgical variables. Before the advent of short‐term ventricular assist
devices (VADs) and extra‐corporeal membrane oxygenation (ECMO) support after transplant,
severe EGF was likely considered to be fatal. Currently, the use of mechanical circulatory
support (MCS) devices as treatment of GD is more widely well accepted and adopted when‐
ever maximal medical management is not sufficient to support the newly transplanted graft.
In this chapter, we will focus on actual indications, surgical strategies, and future perspectives
of veno‐arterial ECMO as a bridge to graft recovery in both pediatric and adult populations.
2. Clinical background and epidemiology
The exact incidence of PGD has been unknown until 2013 due to the lack of standardization
of diagnostic criteria according to the historical observational studies as stated by the above
mentioned ISHLT consensus paper [1]. However, the ISHLT registry data always offered
specific information concerning epidemiology and clinical characteristics of PGD by time. The
examination of early mortality after heart transplant documented in the registry shows that
66% of the death that occurs in the first 30 days after transplant are due to “graft failure” and
“multi‐organ dysfunction” [1]. Most of these events are probably the result of fatal PGD. An
analysis of the United Network for Organ Sharing (UNOS) database was conducted for
transplants occurring from 1999 to 2007 (n = 16,716) [3]. For this analysis, PGD was defined by
“hard outcomes,” meaning postoperative death or retransplant, where the incidence of PGD
was 2.5%. In this PGD group, 85% were due to deaths and 15% were due to retransplants [3].
A closer look at early mortality from the ISHLT revealed that more than 100,000 patients who
received Htx between 1982 and 2011 shows that approximately 10% of patients dies within
30 days of transplant, and this number increases to 14% after 90 days [1]. The risk of 30‐day
and 90‐day mortality was the highest in retransplant (18% and 22%) and congenital heart
disease (17% and 21%), intermediate in valvular cardiomyopathy (14% and 18%), and the
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lowest in ischemic (10% and 14%) and non‐ischemic (8% and 12%) cardiomyopathy patients
[1]. Increasing recipient age is a known risk factor associated with intermediate‐term and long‐
term mortality after heart transplant; however, 30‐day and 90‐day mortality varies little in
patients of different age groups, including patients older than 70 years. Sizable majority of
early post‐transplant deaths likely results from PGD. The recent reduction of early post‐
transplant mortality might have resulted from lower incidence and/or better treatment of PGD.
There are considerable differences in early post‐transplant mortality in patients who receive
transplants for different heart disease etiologies, and early post‐transplant mortality continues
to represent a significant problem despite better survival. Concerning epidemiological data of
Htx in children a retrospective review showing ECMO need in the early post‐transplant period
at Denver Children's Hospital, Aurora, Colorado. From 1990 to 2007, 310 children underwent
Htx, and 28 children who underwent transplantation (9%) were placed on ECMO for postop‐
erative primary graft failure [4]. They conclude that primary graft failure requiring mechanical
circulatory support in the early period after transplantation is not uncommon in children (9%),
and a long ischemic time is a major risk factor of graft dysfunction [4]. Pediatric cardiac
allografts can be successfully salvaged by ECMO in a reasonable proportion of patients (54%)
[4].
2.1. Pathogenesis
The transplant process may lead to donor heart graft several kinds of insults due to:
– Brain death and its sequelae in the donor.
– Hypothermic ischemia during transport.
– Warm ischemia during implant surgery.
– Reperfusion injury after release of the aortic cross‐clamp in the recipient.
Systemic factors in the recipient determine a “hostile” environment that further compro‐
mises donor heart function after reperfusion. Associated with brain death in the donor,
there is a series of events that result in impaired myocardial contractility and sensitize the
heart to ischemia‐reperfusion injury. An example is the intense release of myocardial nor‐
epinephrine immediately after brain death that causes cytosolic and mitochondrial calci‐
um overload [5]. Mitochondrial calcium overload may activate autophagy, apoptosis, or
necrosis [6]. During donor resuscitation, administration of exogenous catecholamines may
determine a reduction of myocardial β‐receptor sensitivity and an activation of multiple
pro‐inflammatory mediators, including complement [7–9]. Referring to hypothermic ische‐
mia, during transport most donor hearts are stored in a cold preservation solution and
transported on ice. Hypothermia slows but does not stop cellular metabolism, so progres‐
sive ischemic injury is an inevitable consequence of prolonged static storage. In addition,
the absence of normal aerobic metabolism arrests the activity of transmembrane Na+/K+
adenosinetriphosphatase pump consequently the switch to anaerobic metabolism during
cold storage causes a rapid decline in high‐energy phosphates and development of lactic
acidosis [10]. Na+/H+ exchanger is activated by intracellular acidosis and it exchanges H+
for Na+ across the cell membrane. The increasing of intracellular Na+ determines an accu‐
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mulation of intracellular Ca2+ by activation of the Na+/Ca+ exchanger [11]. Other factors,
recipient related, contribute to early graft dysfunction. It is possible to find two clinical
conditions. The first is the presence of a high pulmonary vascular resistance in the recipi‐
ent [12, 13]. In this case, the graft failure is considered secondary (to a known recipient
factor) rather than primary. However, even with recipient pulmonary pressures and resis‐
tances within the accepted ranges for heart transplantation, a lower degree of pulmonary
hypertension correlates with a lower incidence of PGD. The second scenario is character‐
ized by activation of the systemic inflammatory response in the recipient, which causes
vasodilated systemic circulation that is not responsive to medical therapy [14]. This “vaso‐
plegic” response is associated with risks factors such as mechanical circulatory support
before transplantation, large transfusion requirements, and prolonged cross‐clamp time. In
this circumstance, the “hostile environment” of the recipient results in PGD. The patho‐
physiology of PGD in this setting is not so clear, but it could involve the multiple action
of many pro‐inflammatory cytokines leading to upregulation of inducible nitric oxide syn‐
thase or indoleamine dioxygenase, with overproduction of nitric oxide or other endoge‐
nous vasodilators [14, 15]. The multiple risk factors for PGD include not only donor and
perioperative factors but also recipient characteristics, confirming the multifaceted nature
Donor risk factors Recipient risk factors Surgical procedural risk factors
• Age
• Cause of death
• Trauma
• Cardiac dysfunction
• Inotropic support
• Comorbidities:
(diabetes,
hypertension)
• Drug abuse
• LV hypertrophy
• Valvular disease
• Hormone treatment
• CAD
• Sepsis
• Troponin trend
• Hypernatremia
• Age
• Weight
• Mechanical support
• Congenital heart disease
• Multiple reoperation
• LVAD explant
• Comorbidities:
(renal/liver
dysfunction)
• Ventilator dependent
• Multiorgan transplant
• Elevated PVR
• Allosensitization
• Infection
• Retransplant
• Ischemia time
• Donor‐recipient mismatch
• Weight mismatch
• Experience of procurement team and center volume
• Cardioplegic solution
• Increased blood transfusion
• Elective vs. emergency
transplant
Table 1. Risk factors for EGF.
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of PGD. The risk factors (Table 1) for PGD related to recipient are: age, parameters re‐
flecting pulmonary hypertension and more severe pre‐transplant condition, including de‐
pendence on intravenous inotropic support, mechanical support and mechanical
ventilation. Donor factors include age, female donor, and cause of brain death. Procedural
factors are represented by ischemic time and donor‐to‐recipient weight mismatch. The
RADIAL score (Table 2) is today the only validated scoring system for the prediction of
PGD [16]. This predictive model was obtained after multivariate analysis of independent
risk factors for PGD in a single‐center derivation cohort of 621 heart transplants per‐
formed from 1984 to 2006. Six factors with similar influence were chosen to form the acro‐
nym RADIAL: four of these are related to the recipient: right atrial pressure (4–10 
mmHg), age (4–60 years), diabetes and inotropic support dependence; and two are associ‐
ated with the donor: age (4–30 years) and length of ischemia time (4–240 min). The pres‐
ence of each of these factors in an individual patient adds one point to the final score.
According to the RADIAL model, there are three groups with low (0–1 points), medium
(2 points), and high (>3 points) risk for PGD.
R (recipient) Right atrial pressure >10 mmHg 1
A (recipient) Age >60 years 1
D (recipient) Diabetes Diagnosis/treatment 1
I (recipient) Inotropic support dependence 1
A (recipient) Age >30 years 1
L (recipient) Length of ischemia >240 min 1
Low risk for PGD (0–1) points
Medium risk for PGD (2) points
High risk for PGD (>3) points
Table 2. Radial score.
2.2. Classification
According to the consensus statement [1], graft dysfunction should be classified into PGD or
secondary graft dysfunction (SGD) where there is a discernible cause such as hyperacute
rejection, pulmonary hypertension, or known surgical complications (e.g., uncontrolled
bleeding; Table 3). It is necessary to made the diagnosis of PGD within 24 h after completion
of the cardiac transplant surgery. There is an important difference between treatment of
patients with RV failure and LV failure, so it was decided to divide PGD into two entities:
PGD‐LV, which includes LV and biventricular failure, and PGD‐RV alone (Table 3). Finally,
it was created a grading system for PGD‐LV, which includes the descriptors of mild, moderate,
and severe dysfunction. These were carefully defined with the use of hemodynamic variables,
echocardiography results, level of inotropic support, and need for mechanical circulatory
support. Because RV failure can often be more difficult to quantify, there are no grades for the
severity of PGD‐RV.
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Primary graft dysfunction (PGD) Secondary graft dysfunction
a. PGD‐left ventricle
(PGD‐LV): includes [21]
left and biventricular
dysfunction
b. PGD‐right ventricle
(PGD‐RV): includes
right ventricular
dysfunction alone
Occurs when there is a discernible cause for graft dysfunction (e.g.,
hyperacute rejection, pulmonary hypertension, known surgical
complication)
PGD‐left ventricle
(PGDLV):
Mild PGD‐LV: one of
the following criteria
must be met
LVEF < 40% by echocardiography, or hemodynamics with RAP > 15 
mmHg, PCWP > 20 mmHg, CI < 2.0 L/min/m2 (lasting more than 1 h)
requiring low‐dose inotropes
Moderate PGD‐LV:
must meet one criterion
from I and another
criterion from II:
I. One criteria from the following: left ventricular ejection fraction < 
40%, or hemodynamic compromise with RAP > 15 mmHg, PCWP > 20 
mmHg, CI < 2.0 L/min/m2, hypotension with MAP < 70 mmHg (lasting
more than 1 h).
II. One criteria from the following:
*High‐dose inotropes—Inotrope score > 10a or
**Newly placed IABP (regardless of inotropes)
Severe PGD‐LV Dependence on left or biventricular mechanical support including
ECMO, LVAD, BiVAD, or percutaneous LVAD. Excludes requirement
for IABP
PGD‐right ventricle
(PGDRV):
Diagnosis requires
either both I and
II, or III alone:
I. Hemodynamics with RAP > 15 mmHg, PCWP < 15 mmHg, CI < 2.0 
L/min/m2
II. TPG < 15 mmHg and/or pulmonary artery systolic pressure < 50 
mmHg, or
III. Need for RVAD
BiVAD, biventricular assist device; CI, cardiac index; ECMO, extracorporeal membrane oxygenation; IABP, intra‐aortic
balloon pump; LVAD, left ventricular assist device; PCWP, pulmonary capillary wedge pressure; RAP, right atrial
pressure; RVAD, right ventricular assist device; TPG, transpulmonary pressure gradient.
aInotrope score = dopamine(x1) + dobutamine(x1) + amrinone(x1) + milrinone(x15) + epinephrine(x100) + 
norepinephrine(x100) with each drug dosed in μg/kg/min [k2].
Table 3. Classification of graft dysfunction.
2.3. Pharmacologic and mechanical management
Before the introduction of short‐term VAD support and ECMO after Htx, PGD was frequently
fatal except for that cases where emergency salvage retransplantation was possible. D’Ales‐
sandro et al. from La Pitié‐Salpétrière in Paris retrospectively evaluated the use of ECMO
temporary support as a treatment for PGD [17]. They studied 394 patients, who underwent
cardiac transplant between 2000 and 2006. In 90 patients, PGD after transplant occurred. In
this study, PGD was defined as the need for inotrope support with epinephrine and/or the
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necessity for mechanical circulatory support in the postoperative 48 h. Of these 90 patients, 54
received ECMO, 8 used other assist devices, and 28 were treated only with maximal inotropes
[17]. Of those medically treated (i.e., on maximal inotropes only), survival was 46% compared
with a survival of 50% for those on ECMO [17]. These data confirm that ECMO is becoming a
safer and more effective technique to manage patients with PGD. A retrospective analysis of
short‐term VAD use after transplantation found that in 38 patients from 2003 to 2008 who have
been implanted with the CentriMag device (Levitronix, Waltham, MA) for PGD survival was
50% at 30 days and 32% at 1 year [18]. Earlier implantation of the device after transplant seemed
to correlate with improved survival, and all survivors were supported with the device for no
more than 30 days [18]. In summary, medical treatment of PGD consists of inotrope and
vasodilator support and these are considered the first line therapy for PGD and may be helpful
for milder cases of PGD. ECMO and other mechanical circulatory support are the only effective
options for more severe cases, appearing to reduce mortality compared with other treatments.
From the data, early intervention and short‐term support appears to be associated with
improved survival.
3. Indication of ECMO in EGF
EGF is the main cause of early mortality after transplantation. Hemodynamic deterioration
caused by cardiogenic shock due to the pump failure unresponsive to inotropes has a cata‐
strophic progression if not corrected in time [2]. As the pathophysiology of EGF is often
unclear, specific treatment remains still challenging and the choice of the most suitable support
option (e.g., ventricular assist device [VAD] or extracorporeal membrane oxygenation
[ECMO]) remains controversial. In particular, ECMO support, even if associated with mor‐
tality and a high rate of morbidity (such as bleeding, ischemic or thromboembolic events and
infections), is considered a valid therapeutic route [19, 20].
3.1. Adult population
Actually, there is not a real or unique indication for ECMO implanting in case of EGF. What
we can consider are the single centers experience. Routinely, after exclusion of surgical
problems, the first line treatment starts using inotropic drags such as milrinone, epinephrine,
and dopamine. In case of hard weaning from CPB machine because of unstable, hemodynamics
should be considered the use of intra‐aortic balloon pump (IABP) and prepare the patient for
ECMO implantation (Figure 1). In the Cedars‐Sinai Heart Institute, for example, they place on
ECMO if cardiac index remains <2.5 L/min/m2 with central venous pressure and left atrial
pressure >12 mmHg and a mean arterial pressure <65 mmHg. The approach of the Columbia
University at the management of PGD has evolved: most patients now receive BiVAD support,
usually a C‐Mag BiVAD with left apical cannulation. More recently ventricular‐arterial ECMO
has also become a more common mode of support. The median length of device support at
their transplant center was 7 days, with an in‐hospital mortality of 51%. Only 5.7% survived
to re‐transplantation [1].
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3.2. Pediatric population
ECMO represents the most commonly used method of mechanical circulatory support in the
post‐transplantation period of pediatric patients [21]. In the same way of the adult, also for the
pediatric population, the indications for the ECMO implantation are not clear. In almost all
centers, the extracorporeal membrane oxygenation is started in the operating room because of
the inability to wean from cardiopulmonary bypass, and only a few cases required ECMO in
the first 48 h after transplantation requiring a cannulation in the cardiac intensive care unit [4].
In particular, as reported by Tissot et al. [4], the timing of ECMO cannulation is not predictive
of outcome. In their population, in fact, the survival is not significantly different between
patients started on ECMO in the operating room with those cannulated in the first 48 h after
transplantation for hemodynamic instability or cardiac arrest in the cardiac intensive care unit.
This is in contrast with Galantowicz et al. [22], who reported no chance of survival if the cardiac
allograft could not support the patient after cardiopulmonary bypass.
4. Surgical approach
Mechanical circulatory support has evolved markedly over recent years even in terms of
surgical techniques. In particular, ECMO support can be deployed peripherally or centrally,
using a traditional or minimally‐invasive approach. There is still a great debate about the
cannulation site strategies (Table 1). The central cannulation has several advantages such as
full antegrade outflow and avoidance of peripheral ischemic complications [23]. However, it
Figure 1. Decision algorithm for ECMO implantation for EGF.
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leads to an high risk for bleeding, tamponade, and infection [24]. These are the main reasons
why a lot of centers adopt a peripheral setting.
4.1. Peripheral cannulation
For veno‐arterial ECMO installation, a femoral vein and a femoral artery are usually used for
vascular access. The correct position of the venous cannula tip is the mid‐right atrium to have
an homogenous drainage of venous blood from both caval veins. The femoral arterial cannula
should be fully introduced till its tip reaches the common iliac artery, in adults (Figure 2).
Commonly, in our center, we use a DLP Biomedicus 15–19 Fr (Medtronic Inc., Minneapolis,
MN) cannula for the femoral artery, and a DLP Biomedicus 17–23 Fr (Medtronic Inc.) cannula
inserted into the femoral vein for the venous drainage [25]. Both insertions are performed using
the Seldinger technique after anterior vessel wall exposure and secured with pledgeted,
reinforced purse string prolene sutures. Combined IABP support is additionally adopted in
the peripheral ECMO population to indirectly “vent” the left ventricle and avoids the pulmo‐
nary edema. For peripheral cannulation, a continuous‐wave Doppler image of the tibial artery
flow and pulsatility should be acquired every 2 days, in the presence of a consultant vascular
surgeon, to evaluate and provide a correct distal leg perfusion.
Although, as described above, the peripheral cannulation reduces the risk of bleeding and of
infection, it can lead to important lower limb ischemia and the so‐called “watershed phenom‐
enon.” The “native” flow meet the retrograde blood flow from the arterial cannula somewhere
between the ascending aorta and the renal arteries at a point called the “watershed.” All areas
distal to this zone received blood oxygenated by the ECMO; meanwhile, the upper part
receives blood from the left ventricle depending on respiratory function of the lung which can
be severely compromised [26]. In an effort to minimize these matters, some centers reported
on the use of a side graft sutured on the axillary artery as arterial return for ECMO peripheral
setting. The advantages include: a low grade of atherosclerosis vessel disease, an antegrade
flow into the aorta, and a preferential delivery of oxygenated blood into the heart and brain
[27].
Figure 2. Peripheral ECMO setting (A: intra‐operative direct cannulation; B: intra‐operative percutaneous approach; C:
setting).
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4.2. Central cannulation
The easiest way to perform a central approach for ECMO implantation after Htx is to re‐utilize
the cannulas adopted for aortic arterial return and atrial venous drainage during the cardio‐
pulmonary bypass (CPB). Usually, the aortic cannula is left in situ to avoid new aortic
puncturing, while the venous cannula is placed into the right atrium through its lateral wall.
At our center, the central cannulation is performed using the right atrium, through its lateral
wall as access, and the left atrium, between the right pulmonary veins as access, for venous
drainage [25]. The employed cannulae are two 28‐Fr wire‐reinforced angled veno‐atrial
cannula (Jostra Venous Catheter OD; Maquet Cardiopulmonary AG, Hirrlingen, Germany)
for both atria. The outflow cannula is always positioned into the ascending aorta [straight aortic
perfusion cannula (22 or 24 Fr); Edwards Lifesciences LLC, Irvine, CA]. All cannulas are
secured with pledgeted, reinforced purse string prolene sutures, tunneled through sub‐costal
incisions to allow chest closure, and then connected to the circuit, avoiding air in the system.
In case of graft isolated right ventricular failure (RVF) and pre‐transplant recipient severe
pulmonary hypertension, the extracorporeal right‐to‐left atrium bypass (ECRLAB) ECMO
setting may be adopted (Figure 3) [25]. Briefly, the cannulation is performed centrally, using
the right atrium for venous drainage and the left atrium, between the right pulmonary veins,
for arterial return. The cannulae are two 28‐Fr wire‐reinforced angled veno‐atrial cannula
(Maquet) for both atria. The conventional circuits, with the inflow cannula in the right atrium
and the outflow cannula in the pulmonary artery, could not completely decompress the right
heart in case of high pulmonary arterial pressures, presumably because no blood entering the
chamber can be ejected across the pulmonary valve. ECRLAB improves the right‐sided
pressures, showing that the component of the right ventricular afterload is “reversible” [25].
ECRLAB appears as well, by increasing both cardiac output and return to the left atrium and
ventricle, to improve end organ function avoiding any eventual multiple organ failure
syndrome (MOF).
Figure 3. Central ECMO setting (A: setting; B: intra‐operative picture).
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4.3. Minimally invasive
A challenging option to reduce the ECMO‐related risk of complications is the adoption of
minimally invasive surgical approaches. There are few reports in the literature. In a recent
paper, Weymann et al. describe their technique [28]. After a small right‐sided thoracotomy at
the eighth intercostal space, flexible arterial and venous cannulas are tunneled. A sewing ring
is secured to the right atrium and a tube graft is anastomosed to the ascending aorta. Following
full‐dose heparinization, the arterial cannula is inserted with the tip into the vascular graft for
the ascending aorta and the venous cannula via the ring into the right atrium. After de‐airing,
the central extracorporeal life support is set at full flow. So far, this surgical approach has not
been described in patients who underwent ECMO implantation as treatment of early graft
failure, but it might be considered a valid idea for future implantations.
5. Weaning protocol
There are no standardized methods or techniques with regards to weaning ECMO. Usually,
the factors indicating cardiac recovery, and so the possibility of weaning from the ECMO, are:
increasing blood pressure, falling central venous and/or pulmonary pressures, and improving
of cardiac contraction [23]. It is so useful reassess the myocardial function every 24/48 h with
TTE, trans‐thoracic echocardiography / TEE, trans‐esophageal echocardiography in addition
to daily hemodynamics. It would be reasonable to reduce pump flows in 0.5 L decrements to
2 L/min over 36–48 h checking the above mentioned variables. The weaning protocols change
from center to center according to the personal experience. Lima et al. [29], for example,
routinely use the intra‐aortic balloon pump for ECMO weaning. At our institution, full ECMO
flow is instituted for at least 72 h [25]. Criteria for weaning include an SvO2 ≥ 70%, a hematocrit
of 28–30%, the absence of bleeding or tamponade, the absence of left heart distension, im‐
provement in contraction of both ventricles, normal blood lactate levels (<1.5 mmol/L), and a
normal urine output (>80 mL/h). A gradual weaning by reducing the ECMO flow by 10% every
∼12 h is our main strategy, together with close TEE and Swan‐Ganz catheter examinations.
Once an ECMO flow of 1.5 L/min/m2 is reached, in the presence of two or more consultant
surgeons, the pump flow is radically reduced at 0.5 L/min/m2 for ∼30 min. If the hemody‐
namics in terms of systemic arterial pressure (mean pressure >60 mmHg), LV contractility (EF
>40%), aortic blood flow time‐velocity integral >10 cm, central venous pressure (10–12 mmHg),
wedge pressure (10–12 mmHg) and SvO2 (>70%) show no significant changes without the
addition of new inotropes, the heparin is stopped, and ECMO support is removed in the
operating room within the next 3 h [25].
6. Outcomes
In case of primary graft failure, when all pharmacological options fail, ECMO system
represents surely a good option in cardiac surgeon's hands to secure a valid circulatory
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support. Outcomes in both subtypes, adult and pediatric population, vary among the different
centers (Table 4). This may be related to several aspects such as the time of implantation and
surgical techniques.
Transplantation center Year ECMO in PGF/
total cardiac
transplants
Surgical approach
Cedars‐Sinai Heart Institute [1] 2005–2012 8/555 —Central cannulation: 100%
—Peripheral cannulation: 0
Instituto de Cardiologia do Distrito
Federal, Brasília [29]
2007–2013 11/71 —Central cannulation: 81.8%
—Peripheral cannulation: 18.2%
Heart Center Leipzig [35] 1997–2011 28/298 —Central cannulation: 0
—Peripheral cannulation: 100%
Cardiac surgery and Heart
Transplant Unit (ISMETT),
Palermo [30]
2006–2013 18/114 —Central cannulation: 77.8%
—Peripheral cannulation: 16.7%
—Central arterial cannulation
and peripheral venous cannulation:
5.5%
Cleveland Clinic [36] 1990–2009 43/1417 —Central cannulation: 0
—Peripheral cannulation: 100%
The Alfred Hospital,
Melbourne [37]
2000–2009 39/239 —Central cannulation: 66.6%
—Peripheral cannulation: 41%
Groupe hospitalier Pitié‐
Salpétrière [17]
2000–2006 54/394 —Central cannulation: 48.1%
—Peripheral cannulation: 51.9%
S. Orsola‐Malpighi Hospital
[38]
2002–2007 11/188 —Central cannulation: 54.6%
—Peripheral cannulation: 45.4%
Table 4. Outcomes of ECMO support as treatment of EGF.
6.1. Adult
In literature, the successful ECMO weaning rate ranges from 68% to 82% and corresponds to
a hospital mortality rate of 50%. In the experience reported by Santise et al. [30], 13 patients
(72.2%—13/18) were weaned from the mechanical circulatory support, and eight of them (44%)
were discharged home. The causes of death of the patients weaned from ECMO were multi‐
organ failure, sepsis and acute mycotic rupture of pulmonary artery. Also the group of La Pitié‐
Salpétrière [17], in an older paper, report good results after ECMO implantation. Among the
54 patients supported with ECMO, 36 were weaned from the assistance and 27 were dis‐
charged. In this study, patients treated with ECMO had the same 1‐year conditional survival
as patients not having suffered EGF: 94% at 3 years.
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6.2. Pediatric
Early primary graft failure after Htx in children is associated with significant rates of mortality
and morbidity. Extracorporeal membrane oxygenation is widely used and is well established
to support circulatory function in children with post‐cardiotomy low cardiac output syndrome
[31]. The manuscript with the largest series on pediatric heart transplantation is that of Tissot
from Denver Children's Hospital, Aurora, Colorado [4]. They retrospectively analyzed the
indications and outcome of extracorporeal membrane oxygenation for early primary graft
failure and determined its impact on long‐term graft function and rejection risk. From 1990 to
2007, 28 (9%) of 310 children who underwent transplantation for cardiomyopathy or congenital
heart disease required ECMO support. Fifteen children were successfully weaned off ECMO
and discharged alive (54%). This is comparable to what has been previously reported in the
pediatric population [21, 32, 33].
Mean duration of ECMO was 2.8 days for survivors (median 3 days) compared with 4.8 days
for non‐survivors (median 5 days). The duration of cannulation was so important in this series,
with no child surviving ECMO support for >4 days. The long‐term outcome in those patients
supported by ECMO for primary graft failure and surviving to hospital discharge was
excellent. There was, in fact, 100% 3‐year survival in the ECMO survivor group, with 13
patients (46%) currently alive at a mean follow‐up of 8.1 ± 3.8 years.
7. Conclusions and perspectives
PGD is the main cause of early mortality after Htx. Hemodynamic deterioration caused by
cardiogenic shock due to pump failure unresponsive to inotropes has a catastrophic progres‐
sion if not solved in time. Early institution of ECMO allows myocardial graft function recovery
despite multifactorial insults and prevents the development of an eventual multisystem organ
failure which would otherwise occur in case of a prolonged period of uncorrected cardiogenic
shock [34]. In addition to the short‐term effects, it has been observed that ECMO implantation,
as a bridge to graft recovery after transplantation, can be used without influencing the long‐
term outcome of this high‐risk postoperative cohort of patients. Currently, we take advantage
from a wide available range of surgical options for ECMO setting. However, we are still too
far from the ideal mechanical support device as routine and well‐accepted treatment strategy.
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